Oral fidaxomicin versus vancomycin for Clostridioides difficile infection

被引：2
|
作者：
Long, Brit [1 ]
Gottlieb, Michael [2 ]
机构：
[1] Brooke Army Med Ctr, Dept Emergency Med, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA
[2] Rush Univ, Med Ctr, Dept Emergency Med, Chicago, IL 60612 USA
来源：
ACADEMIC EMERGENCY MEDICINE | 2022年 / 29卷 / 12期
关键词：
Clostridioides difficile; Clostridioides difficile infection; diarrhea; gastroenterology; infectious diseases; EPIDEMIOLOGY; BURDEN;
D O I：
10.1111/acem.14600
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1506 / 1507
页数：2
相关论文
共 50 条
  • [1] Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile
    Rinaldi, Alyssa
    Reed, Erica E.
    Stevenson, Kurt B.
    Coe, Kelci
    Smith, Jessica M.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (04) : 993 - 998
  • [2] A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection
    Diaz-Pollan, Beatriz
    Molina, Sergio Carrasco
    Marcelo, Cristina
    Grela, Alejandro de Gea
    Martinez-Martin, Patricia
    Jimenez-Gonzalez, Maria
    Ramos, Francisco Moreno
    Mora-Rillo, Marta
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [3] Fidaxomicin versus Vancomycin for Clostridium difficile Infection
    Louie, Thomas J.
    Miller, Mark A.
    Mullane, Kathleen M.
    Weiss, Karl
    Lentnek, Arnold
    Golan, Yoav
    Gorbach, Sherwood
    Sears, Pamela
    Shue, Youe-Kong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 422 - 431
  • [4] Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
    Jiang, Yiling
    Sarpong, Eric M.
    Sears, Pamela
    Obi, Engels N.
    [J]. INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 111 - 126
  • [5] Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
    Yiling Jiang
    Eric M. Sarpong
    Pamela Sears
    Engels N. Obi
    [J]. Infectious Diseases and Therapy, 2022, 11 : 111 - 126
  • [6] Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials
    Tashiro, Sho
    Mihara, Takayuki
    Sasaki, Moe
    Shimamura, Chiaki
    Shimamura, Rina
    Suzuki, Shiho
    Yoshikawa, Maiko
    Hasegawa, Tatsuki
    Enoki, Yuki
    Taguchi, Kazuaki
    Matsumoto, Kazuaki
    Ohge, Hiroki
    Suzuki, Hiromichi
    Nakamura, Atsushi
    Mori, Nobuaki
    Morinaga, Yoshitomo
    Yamagishi, Yuka
    Yoshizawa, Sadako
    Yanagihara, Katsunori
    Mikamo, Hiroshige
    Kunishima, Hiroyuki
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (11) : 1536 - 1545
  • [7] Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study
    Gentry, C. A.
    Nguyen, P. K.
    Thind, S.
    Kurdgelashvili, G.
    Skrepnek, G. H.
    Williams, R. J., II
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (08) : 987 - 993
  • [8] Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection
    Liao, J. Xin
    Appaneal, Haley J.
    Vicent, Martie L.
    Vyas, Ami
    LaPlante, Kerry L.
    [J]. PHARMACOTHERAPY, 2022, 42 (11): : 810 - 827
  • [9] Oral Vancomycin as Secondary Prophylaxis for Clostridioides difficile Infection
    Bao, Hongkai
    Lighter, Jennifer
    Dubrovskaya, Yanina
    Merchan, Cristian
    Siegfried, Justin
    Papadopoulos, John
    Jen, Shin-Pung
    [J]. PEDIATRICS, 2021, 148 (02)
  • [10] Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile
    Turner, Nicholas A.
    Warren, Bobby G.
    Gergen-Teague, Maria F.
    Addison, Rachel M.
    Addison, Bechtler
    Rutala, William A.
    Weber, David J.
    Sexton, Daniel J.
    Anderson, Deverick J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 648 - 656
12345